Armistice Capital’s Biolase, Inc. BIOL Stock Holding History

Armistice Capital’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,990	Closed	-$1.7M	–	246
2022 Q3	$1.7M	Buy	6,990 +529	+8%	+$211K	0.03%	128
2022 Q2	$2.96K	Buy	+6,461	New	+$3.55M	0.05%	111

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Armistice Capital's BIOL Position: Q4 2022 in Review

Armistice Capital sold out of Biolase, Inc. (BIOL) in Q4 2022, closing a stake of 6,990 shares — an estimated $1.7M sold.

Armistice Capital first reported a position in BIOL in Q2 2022 and held it in 2 quarters. The position peaked at $1.7M in Q3 2022. 19 funds tracked by Wall St. Rank hold BIOL as of Q4 2022.

Armistice Capital reported no remaining Biolase, Inc. position as of Q4 2022 after selling out during the quarter.
Armistice Capital sold 6,990 Biolase, Inc. shares in Q4 2022, an estimated $1.7M.
Armistice Capital first reported a position in Biolase, Inc. in Q2 2022 and held it in 2 quarters.
Armistice Capital's Biolase, Inc. position peaked at $1.7M in Q3 2022.
19 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2022.

Based on Armistice Capital's 13F filing for Q4 2022, filed 14 Feb 2023.